Top-Rated StocksTop-RatedNASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $34.38 -1.46 (-4.08%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxcyte Stock (NASDAQ:PCVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxcyte alerts:Sign Up Key Stats Today's Range$31.27▼$36.2650-Day Range$28.04▼$81.6852-Week Range$27.66▼$121.06Volume1.16 million shsAverage Volume1.82 million shsMarket Capitalization$4.43 billionP/E RatioN/ADividend YieldN/APrice Target$136.50Consensus RatingBuy Company OverviewVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More… Vaxcyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScorePCVX MarketRank™: Vaxcyte scored higher than 61% of companies evaluated by MarketBeat, and ranked 521st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vaxcyte's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.21) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -7.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -7.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxcyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.22% of the float of Vaxcyte has been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Vaxcyte has recently increased by 2.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.22% of the float of Vaxcyte has been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Vaxcyte has recently increased by 2.41%, indicating that investor sentiment is decreasing. News and Social Media3.6 / 5News Sentiment1.41 News SentimentVaxcyte has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Vaxcyte this week, compared to 7 articles on an average week.Search Interest12 people have searched for PCVX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,946,720.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Stock News HeadlinesVaxcyte Appoints Dr. Olivier Brandicourt to BoardMay 1 at 9:05 AM | tipranks.comVaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine DevelopmentMay 1 at 8:18 AM | quiverquant.comVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.May 1, 2025 | Stansberry Research (Ad)Vaxcyte Appoints Dr. Olivier Brandicourt to Board of DirectorsMay 1 at 8:00 AM | globenewswire.comIs Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?April 29 at 9:15 PM | insidermonkey.comCantor Fitzgerald Estimates Vaxcyte FY2025 EarningsApril 25, 2025 | americanbankingnews.comCommit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using OptionsApril 23, 2025 | nasdaq.comCantor Fitzgerald Initiates Coverage of Vaxcyte (PCVX) with Overweight RecommendationApril 23, 2025 | msn.comSee More Headlines PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $81.86 on January 1st, 2025. Since then, PCVX shares have decreased by 58.0% and is now trading at $34.3790. View the best growth stocks for 2025 here. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) announced its quarterly earnings results on Tuesday, February, 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. Read the conference call transcript. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an initial public offering on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's top institutional shareholders include Brown Advisory Inc. (0.44%), Principal Financial Group Inc. (0.36%), Bank of New York Mellon Corp (0.32%) and Allspring Global Investments Holdings LLC (0.26%). Insiders that own company stock include Jeff Fairman, Jim Wassil, Grant Pickering, Andrew Guggenhime, Mikhail Eydelman, Paul Sauer, Elvia Cowan, Teri Loxam, Halley E Gilbert and Heath Lukatch. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings2/25/2025Today4/30/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCVX CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$136.50 High Stock Price Target$163.00 Low Stock Price Target$90.00 Potential Upside/Downside+280.9%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-402,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.53% Return on Assets-22.20% Debt Debt-to-Equity RatioN/A Current Ratio17.88 Quick Ratio17.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book2.75Miscellaneous Outstanding Shares128,939,000Free Float120,773,000Market Cap$4.62 billion OptionableOptionable Beta1.26 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:PCVX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.